Target's General Information
Target ID T83369
Target Name Coagulation factor IX (F9)
Synonyms Plasma thromboplastin component; PTC protein; Factor IX; Christmas factor
Target Type Successful
Gene Name F9
Biochemical Class Peptidase
UniProt ID FA9_HUMAN
Target's Expression Profile in Disease Related Tissue between Patients and Normal People
Disease Coronary artery disease
Example drug RB-006 Discontinued in Phase 3 [1], [2], [3]
Tissue Peripheral blood
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.13
Z-score: -0.45
P-value: 5.69E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Sepsis
Example drug SB 249417 Discontinued in Phase 1 [2], [3], [4]
Tissue Whole blood
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.02
Z-score: -0.12
P-value: 3.59E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Target's Expression Profile across Various Tissues of Healthy Individual
References
REF 1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019932)
REF 2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 3 NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.
REF 4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010912)

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.